REPORT ID 6227

United States Choroidal Neovascularization Drug Market Report 2017

Publish Date
25-Dec-17
Pages
108
Format
Electronic (PDF)

In this report, the United States Choroidal Neovascularization Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Choroidal Neovascularization Drug in these regions, from 2012 to 2022 (forecast).

United States Choroidal Neovascularization Drug market competition by top manufacturers/players, with Choroidal Neovascularization Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Cellphire, Inc.
    Chrysalis BioTherapeutics, Inc.
    Cleveland BioLabs, Inc.
    Cumberland Pharmaceuticals, Inc.
    Diffusion Pharmaceuticals Inc.
    Eli Lilly and Company
    GNI Group Ltd.
    Humanetics Corporation
    INSYS Therapeutics, Inc.
    Meabco A/S
    Neumedicines Inc.
    Onconova Therapeutics, Inc.
    PharmaIN Corporation
    Pluristem Therapeutics Inc.
    ProCertus BioPharm Inc.
    RDD Pharma Ltd.
    RedHill Biopharma Ltd.
    RxBio, Inc.
    Soligenix, Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    AVMOC-001
    BB-3
    BBT-007
    DG-3
    Entolimod
    EWA-001
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hospital
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Choroidal Neovascularization Drug Market Report 2017
1 Choroidal Neovascularization Drug Overview
    1.1 Product Overview and Scope of Choroidal Neovascularization Drug
    1.2 Classification of Choroidal Neovascularization Drug by Product Category
        1.2.1 United States Choroidal Neovascularization Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Choroidal Neovascularization Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 AVMOC-001
        1.2.4 BB-3
        1.2.5 BBT-007
        1.2.6 DG-3
        1.2.7 Entolimod
        1.2.8 EWA-001
        1.2.9 Others
    1.3 United States Choroidal Neovascularization Drug Market by Application/End Users
        1.3.1 United States Choroidal Neovascularization Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 United States Choroidal Neovascularization Drug Market by Region
        1.4.1 United States Choroidal Neovascularization Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Choroidal Neovascularization Drug Status and Prospect (2012-2022)
        1.4.3 Southwest Choroidal Neovascularization Drug Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Choroidal Neovascularization Drug Status and Prospect (2012-2022)
        1.4.5 New England Choroidal Neovascularization Drug Status and Prospect (2012-2022)
        1.4.6 The South Choroidal Neovascularization Drug Status and Prospect (2012-2022)
        1.4.7 The Midwest Choroidal Neovascularization Drug Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Choroidal Neovascularization Drug (2012-2022)
        1.5.1 United States Choroidal Neovascularization Drug Sales and Growth Rate (2012-2022)
        1.5.2 United States Choroidal Neovascularization Drug Revenue and Growth Rate (2012-2022)

2 United States Choroidal Neovascularization Drug Market Competition by Players/Suppliers
    2.1 United States Choroidal Neovascularization Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Choroidal Neovascularization Drug Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Choroidal Neovascularization Drug Average Price by Players/Suppliers (2012-2017)
    2.4 United States Choroidal Neovascularization Drug Market Competitive Situation and Trends
        2.4.1 United States Choroidal Neovascularization Drug Market Concentration Rate
        2.4.2 United States Choroidal Neovascularization Drug Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Choroidal Neovascularization Drug Manufacturing Base Distribution, Sales Area, Product Type

3 United States Choroidal Neovascularization Drug Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Choroidal Neovascularization Drug Sales and Market Share by Region (2012-2017)
    3.2 United States Choroidal Neovascularization Drug Revenue and Market Share by Region (2012-2017)
    3.3 United States Choroidal Neovascularization Drug Price by Region (2012-2017)

4 United States Choroidal Neovascularization Drug Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Choroidal Neovascularization Drug Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Choroidal Neovascularization Drug Revenue and Market Share by Type (2012-2017)
    4.3 United States Choroidal Neovascularization Drug Price by Type (2012-2017)
    4.4 United States Choroidal Neovascularization Drug Sales Growth Rate by Type (2012-2017)

5 United States Choroidal Neovascularization Drug Sales (Volume) by Application (2012-2017)
    5.1 United States Choroidal Neovascularization Drug Sales and Market Share by Application (2012-2017)
    5.2 United States Choroidal Neovascularization Drug Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Choroidal Neovascularization Drug Players/Suppliers Profiles and Sales Data
    6.1 Cellphire, Inc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Chrysalis BioTherapeutics, Inc.
        6.2.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Cleveland BioLabs, Inc.
        6.3.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Cumberland Pharmaceuticals, Inc.
        6.4.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Diffusion Pharmaceuticals Inc.
        6.5.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Eli Lilly and Company
        6.6.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 GNI Group Ltd.
        6.7.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Humanetics Corporation
        6.8.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 INSYS Therapeutics, Inc.
        6.9.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Meabco A/S
        6.10.2 Choroidal Neovascularization Drug Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Neumedicines Inc.
    6.12 Onconova Therapeutics, Inc.
    6.13 PharmaIN Corporation
    6.14 Pluristem Therapeutics Inc.
    6.15 ProCertus BioPharm Inc.
    6.16 RDD Pharma Ltd.
    6.17 RedHill Biopharma Ltd.
    6.18 RxBio, Inc.
    6.19 Soligenix, Inc.

7 Choroidal Neovascularization Drug Manufacturing Cost Analysis
    7.1 Choroidal Neovascularization Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Choroidal Neovascularization Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Choroidal Neovascularization Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Choroidal Neovascularization Drug Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Choroidal Neovascularization Drug Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Choroidal Neovascularization Drug Sales Volume Forecast by Type (2017-2022)
    11.3 United States Choroidal Neovascularization Drug Sales Volume Forecast by Application (2017-2022)
    11.4 United States Choroidal Neovascularization Drug Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer